News
05-31-2014, 05:33 AM
Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the presentation of data for its lead drug candidate, ANG1005, a novel paclitaxel-peptide drug conjugate, at the American Society of Clinical Oncology 50th Annual Meeting in Chicago, IL.
More... (http://www.news-medical.net/news/20140531/Angiochem-presents-data-on-ANG1005-paclitaxel-peptide-drug-conjugate-at-50th-ASCO-annual-meeting.aspx)
More... (http://www.news-medical.net/news/20140531/Angiochem-presents-data-on-ANG1005-paclitaxel-peptide-drug-conjugate-at-50th-ASCO-annual-meeting.aspx)